Frederick, MD, U.S.

MedImmune Frederick Manufacturing Center (FMC) Biotech Expansion

MedImmune is a leading biotechnology company and operates as a wholly owned subsidiary of AstraZeneca.

The Frederick Manufacturing Center (FMC) is a large-scale mammalian cell culture manufacturing facility.

Fluor provided construction management, start-up, commissioning, and qualification services for MedImmune's FMC Expansion Project.

The project was recognized in 2011 with two awards by ISPE:

  • Overall ISPE Facility of the Year Awards Overall Winner
  • Facility of the Year for Project Execution


Client's Challenge

MedImmune is among the world's leading biotechnology companies. The company wanted to build a new facility at its existing campus in Frederick, Maryland, to manufacture large-scale mammalian cell culture-based products with a wide range of titers.

The FMC Expansion project leverages the expertise and systems already in place at FMC, which have been used to successfully produce the company's monoclonal antibody.

Fluor's Solution

Fluor provided construction management, start-up, commissioning, and qualification services for the FMC Expansion Project. The new facility, Building 633, is a 337,000 square-foot space on MedImmune's existing campus.

The Fluor team brought cost and schedule certainty to the FMC Expansion Project through understanding and experience in the design and construction of similar facilities.

The final success of the FMC Expansion Project was measured by best-in-class construction safety; on target cost; and Government Post Approval Submittal (PAS) on schedule.

Other success factors included:

  • Proactive project controls approach to monitor potential threats to the project cost and schedule
  • Comprehensive turnover plan that was vetted early in project planning and allowed the team to completely install and transfer 243 systems in a six-month period
  • Integrated construction and management teams completed all turnover activities safely, successfully, and on time



Fluor completed the MedImmune FMC Expansion Project on schedule and within budget.

The Fluor team used proactive planning tools to successfully monitor the project and commission the facility.

The project achieved an outstanding safety record of more than 2.3 million work hours without a single lost-time accident.